Chronic myelogenous leukemia cytogenetic response

Imatinib Mesylate (Gleevec) Tyrosine kinase inhibitor bcr-abl, c-kit Chronic myelogenous leukemia Hematologic and cytogenetic response rate. Phase III GIST ... 

Kantarjian, H. et al.. Hematologic and cytogenetic responses to imafinib mesylate in chronic myelogenous leukemia, N. Engl. J. Med., 346, 645-652, 2002. 

Kantarjian,H.M.,T.L.Smith,S. O Brien,M. Beran, S. Pierce, and M. Talpaz, Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med, 1995.122(4) 254-61. 

Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis results of a phase II study. B/ooc/2002 99 3530-3539. 

Cortes J, Guilhot F, Rosti Get al. Dasatinib (SPRYCEL) in patients (pts) with chronic myelogenous leukemia in aeeelerated phase (AP-CML) that is imatinib-resistant (TM-R) or intolerant (IM-I) updated results of the CA180-005 START-A phase 11 study (Abstract 2160). Blood 2006 108 613a. Cortes J, Rousselot R Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007 109 3207-3213. 

Chronic myelogenous leukemia (CML) patients who have a cytogenetic response have an improved survival. 

TABLE 132—2. Cytogenetic Response Rate Associated with Imatinib in Chronic Myelogenous Leukemia (CML)... 

---